ÂÜÀòÂÒÂ×

Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received his BA from Johns Hopkins University and MD from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University. He has served as an Associate Professor at the USC Keck, and UCSD Medical School. Dr. Spear led multiple oncology programs at Pfizer, then served as CMO and Sr. VP at Nereus Pharmaceuticals, followed by Head of Oncology and Biotherapeutics at Sunovion, VP at Incyte and Sangamo. Prior to Denovo, he was CMO at Poseida developing CAR-T cell and gene therapy products, and a CIRM CAR-T cell principal investigator. He has served on NIH/NCI study section, CPRIT, biotech and pharm advisory boards, IRB/SRC, journal editorial review committees, and authored numerous scientific papers and patent applications.